Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III, Open Label, Randomized, Multicenter Trial of Ofatumumab Added to Chlorambucil Versus Chlorambucil Monotherapy in Previously Untreated Patients With Chronic Lymphocytic Leukemia

NCT00748189 is registered in ClinicalTrials.gov with Novartis Pharmaceuticals as lead sponsor.

NCT NCT00748189
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00748189 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III, Open Label, Randomized, Multicenter Trial of Ofatumumab Added to Chlorambucil Versus Chlorambucil Monotherapy in Previously Untreated Patients With Chronic Lymphocytic Leukemia
Lead sponsor
Novartis Pharmaceuticals
Phase
Phase 3
Overall status
Terminated
Start date
December 22, 2008
Completion date
May 17, 2018
Enrollment
447 (actual)
Sites
154

Conditions

As the registry lists them; a condition with its own page is linked.

leukaemia, lymphocytic, chronic